In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Five years since it launched, advances powered by the National Drug Discovery Centre are helping transform medical research in Australia and fast-tracking development of new home-grown treatments.

Natco Pharma gains FDA approval for generic Bosentan tablets, partnering with Lupin Pharmaceuticals for U.S. marketing.

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

That increase in survival is seen as a major advance in PAH treatment, which has a five-year survival rate of a little over 40%, and is backed up by functional improvements, including a ...

The Massachusetts-based company was aiming to compete with Merck's PAH treatment (MRK.N), opens new tab Winrevair — approved by the FDA in March 2024. Analysts expect Merck's treatment to become ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...